After Lebanon's economic collapse, out-of-pocket payments for bladder cancer care rose by 2,745% and insurers and public payers covered only 17% of the total cost, a modelling study found.
An incidence-based cost-of-illness study of urothelial bladder cancer in Lebanon, using costs from third-party payers and the Ministry of Public Health and modelling clinical management by stage, comparing costs before and after the 2019 collapse from the perspective of payers and households.
Puts a number on how the cost of a common Lebanese cancer moved from insurers to households after 2019.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/